Document is current
Any future updates will be listed below
-
Authors
Fu, Jiaxin
Liang, Cong
Sun, Lixin
Zhao, Hongwei
Cui, Zhumei
Lang, Jinghe
Chen, Chunlin
Liu, Ping
-
Funding
Funding for this research was provided by:
The National Science and Technology Support Program of China (2014BAI05B03, 2014BAI05B03)
The Natural Science Fund of Guangdong Province (2015A030311024, 2015A030311024)
The Science and Technology Plan of Guangzhou (2023B03J0254, 2023B03J0254)
- License Information
-
More Information
Article History
Received: 21 January 2025
Accepted: 7 March 2025
First Online: 14 March 2025
Declarations
:
: The study was accomplished following the ethical principles according to the Declaration of Helsinki 1964. This retrospective study was approved by the Ethics Committee of the Nanfang Hospital of Southern Medical University (approval number NFEC-2017–135 and clinical trial number CHiCTR1800017778; International Clinical Trials Registry Platform Search Port, , registered at 14/08/2018), who deemed that written informed consent was not necessarily due to the retrospective nature of the research and concealment of patient information.
: (1) Adjuvant therapy remains unknown in cervical adenocarcinoma patients. (2) Radical hysterectomy alone can be used to treat cervical adenocarcinoma. (3) Postoperative adjuvant treatment did not improve the outcome.
: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
: We did not involve patients or the public in our work.
: The authors declare no competing interests.
